Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease

Phase 2

Completed

• Conditions: Gastroesophageal Reflux Disease
• Interventions: Device: EndoStim LES Stimulation System

• Registration Number: NCT01578642
• Lead Sponsor: EndoStim Inc.

Brief Summary

The EndoStim Stimulation System is an investigational device intended to improve the lower esophageal sphincter (LES) resting tone and restore LES function in individuals suffering with gastroesophageal reflux disease (GERD).

Detailed Description

EndoStim is developing an investigational medical device specifically designed to deliver electrical stimulation to the LES and has completed two clinical feasibility studies using the EndoStim stimulation system in fifteen subjects.

Acute electrical stimulation resulted in significant LES pressure with no adverse effects reported.

Results of these studies are promising and warrant additional clinical study to evaluate the effectiveness of EndoStim stimulation system to treat GERD over time.

In this study, EndoStim proposes using a fully implantable system. Results of this study are expected to provide confirmation of safety of long-term LES stimulation and may provide long term clinical benefit for GERD patients.

Study Timeline

• Study Start: 2010-09
• Study First Submitted: 2012-04-11
• Study First Submitted QC: 2012-04-15
• Study First Posted: 2012-04-17
• Status Verified: 2013-01
• Primary Completion: 2013-05
• Study Completion: 2013-05
• Last Update Submitted: 2014-02-11
• Last Update Posted: 2014-02-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• Subject is between 21 - 65 years of age.
• Subject has a history of heartburn, regurgitation or both for > 6 months prompting physician recommendation of continual daily use of PPI before study entry.
• Baseline GERD-HRQL heartburn score of ≥ 20 off PPI assessed during the run-in phase.
• Subject has an American Society of Anesthesiologists (ASA) Physical Status Classification I or II (or comparable local classification if any).
• Subject has demonstrated satisfactory symptomatic response to a previous course of GERD therapy (≥ 2 weeks); GERD HRQL heartburn score improvement of ≥ 10 on therapy as assessed during the run in phase.
• Subject has exhibited excessive lower esophageal acid exposure during 24-hour pH-metry off antisecretory therapy performed within 6 months of enrollment; pH < 4 for > 5% of total or > 3% of supine time.
• Subject has a resting LES end expiratory pressure > 5mm Hg and < 15 mm Hg on a high resolution manometry within 6 months of enrollment.
• Subject has esophagitis ≤ Grade C (LA classification) on upper endoscopy within 6 months of enrollment.
• Subject has esophageal body contraction amplitude > 30 mmHg for > 70% of swallows and > 50% peristaltic contractions on high resolution manometry.
• Subject has signed the informed consent form.

Exclusion Criteria

• Subject has non-GERD esophageal motility disorders.
• Subject has gastroparesis.
• Subject has significant multisystem diseases.
• Subject has scleroderma requiring therapy in the preceding 2 years .
• Subject has dermatomyositis requiring therapy in the preceding 2 years.
• Subject has Calcinosis-Raynaud's-esophaguschlerodactyly syndrome requiring therapy in the preceding 2 years.
• Subject has Sjogren's Syndrome requiring therapy in the preceding 2 years.
• Subject has Sharp's Syndrome requiring therapy in the preceding 2 years.
• Subject has persistent esophagitis greater than LA grade C.
• Subject has Barrett's epithelium (> M2; >C1) or any dysplasia.
• Subject has a hiatus hernia larger than 3 cm.
• Subject has a body mass Index greater than 35 kg/m2 .
• Subject has Type 1 diabetes mellitus
• Subject has uncontrolled Type 2 diabetes mellitus (T2DM) defined as HbA1c >9.5 in the previous 6 months, or has T2DM for > 10 years.
• Subject has an autoimmune disorder requiring therapy in the preceding 2 years.
• Subject has suspected or confirmed esophageal or gastric cancer.
• Subject has esophageal or gastric varices.
• Subject has significant cardiac arrhythmia or ectopy or significant cardiovascular disease.
• Subject has an existing implanted electrical stimulator (e.g., pacemaker).
• Subject requires chronic anticoagulant therapy.
• Subject has dysphagia or esophageal peptic structure, excluding Schatzki's ring.
• Subject is pregnant or intends to become pregnant during the trial period.
• Subject is currently enrolled in other potentially confounding research.
• Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.
• History of any malignancy in the last 2 years
• History of previous esophageal or gastric surgery, including nissen fundoplication

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single Arm open label	EndoStim LES Stimulation System	EndoStim LES Stimulation System

Primary Outcome Measures

Name	Time	Method
Primary Safety Endpoint	3 months	Safety will be assessed by incidence and severity of adverse events through 12-week (3 month) follow-up. Included in this assessment will be the proportion of subjects with any of the following outcomes between device implant and completion of the Week 12 evaluation: (1) death, or (2) medical morbidity, including myocardial infarction, pneumonia, wound infection, or perforation requiring hospitalization.
Primary Endpoint: Functionality	Up to 3 months	Functionality of the EndoStim system will be assessed by the ability of the device to initiate stimulation as programmed and to accurately detect the patient's posture. Indication of device detection when the patient is lying horizontally and when standing up will be recorded.

Secondary Outcome Measures

Name	Time	Method
Esophageal Acid Exposure	3 months	Total fractional esophageal acid exposure time with pH \< 4.0. The data on baseline esophageal acid exposure off-therapy, prior to surgical implant of the stimulator and on-stimulation at 12 weeks (3 months) post-implant
GERD-HRQL	3 months	Improvement in GERD-HRQL with LES stimulation at the 12-weeks (3 months) follow-up compared to baseline
GERD Symptoms	3 months	Changes in GERD symptoms as measured by the patient daily symptom-diary as well as the impact of GERD symptoms on quality of life as measured by SF-12 will be compared between baseline assessments and post-implant measures at 12 weeks (3 months).
Lower Esophageal Measures	3 months	The baseline LES end expiratory pressure and the on-stimulation LES end expiratory pressure at 3 months

Trial Locations

Locations (1)

INDISA Clínica da Familia; 🇨🇱 Santiago, Chile